Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 9/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.40 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.39 |
| ▸ | TUBB | P07437 | 3/20 | 0.39 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.39 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.39 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.39 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.39 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.39 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.39 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.39 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.39 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.39 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.39 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.39 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.37 |
| ▸ | STAT3 | P40763 | 2/20 | 0.37 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6450850 | 1.00 | TUBB1 (0.41) | TUBB1NFE2L2TUBB4ATUBBTUBA3C | |
| SCHEMBL918107 | 0.88 | PTGS1 (0.44) | TUBB1NFE2L2TUBB4ATUBBTUBA3C | |
| SCHEMBL918372 | 0.87 | CYP1A1 (0.44) | TUBB1NFE2L2TUBB4ATUBBTUBA3C | |
| SCHEMBL6449536 | 0.87 | CYP1A1 (0.44) | TUBB1NFE2L2TUBB4ATUBBTUBA3C | |
| SCHEMBL6448424 | 0.85 | TUBB1 (0.41) | TUBB1NFE2L2TUBB4ATUBBTUBA3C | |
| SCHEMBL917832 | 0.85 | TUBB1 (0.41) | TUBB1NFE2L2TUBB4ATUBBTUBA3C | |
| SCHEMBL918373 | 0.82 | NFE2L2 (0.61) | TUBB1NFE2L2TUBB4ATUBBTUBA3C | |
| SCHEMBL6453082 | 0.82 | NFE2L2 (0.61) | TUBB1NFE2L2TUBB4ATUBBTUBA3C | |
| SCHEMBL6459887 | 0.82 | NFE2L2 (0.50) | TUBB1NFE2L2TUBB4ATUBBTUBA3C | |
| SCHEMBL918614 | 0.82 | NFE2L2 (0.50) | TUBB1NFE2L2TUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059733-A1 | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues | WELICHEM BIOTECH, INC. | 2005-03-17 | — | — | US | claimed |
| US-7868047-B2 | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues | WELICHEM BIOTECH INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-20100094041-A1 | ANTI-INFLAMMATORY AND PSORIASIS TREATMENT AND PROTEIN KINASE INHIBITION BY HYDROXY STILBENES AND NOVEL STILBENE DERIVATIVES AND ANALOGUES | WELICHEM BIOTECH INC. (CA) | 2010-04-15 | — | — | US | disclosed |
| US-20080139666-A1 | Anti-Inflammatory and Psoriasis Treatment and Protein Kinase Inhibition by Hydroxy Stilbenes and Novel Stilbene Derivatives and Analogues | WELICHEM BIOTECH INC. (CA) | 2008-06-12 | — | — | US | disclosed |
| EP-1554236-A1 | NOVEL BIOACTIVE DIPHENYL ETHENE COMPOUNDS AND THEIR THERAPEUTIC APPLICATIONS | Welichem Biotech Inc. (CA) | 2005-07-20 | — | — | EP | disclosed |
| US-20050059733-A1 | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues | WELICHEM BIOTECH, INC. | 2005-03-17 | — | — | US | disclosed |
| WO-2004031117-A1 | NOVEL BIOACTIVE DIPHENYL ETHENE COMPOUNDS AND THEIR THERAPEUTIC APPLICATIONS | WELICHEM BIOTECH INC. (CA) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059733-A1 | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues | NFKBIA, IKBKB, IKBKE | TUBB1 1060/4885NFE2L2 402/4885TUBB4A 1539/4885 |
| US-20080139666-A1 | Anti-Inflammatory and Psoriasis Treatment and Protein Kinase Inhibition by Hydroxy Stilbenes and Novel Stilbene Derivatives and Analogues | LTK, MMP8, CHUK | TUBB1 1237/4885NFE2L2 1037/4885TUBB4A 1411/4885 |
| US-20100094041-A1 | ANTI-INFLAMMATORY AND PSORIASIS TREATMENT AND PROTEIN KINASE INHIBITION BY HYDROXY STILBENES AND NOVEL STILBENE DERIVATIVES AND ANALOGUES | CHUK, MAP3K8, MAP3K1 | TUBB1 1240/4885NFE2L2 1428/4885TUBB4A 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.